Centerpoint Advisors LLC Has $882,000 Stock Position in Johnson & Johnson $JNJ

Centerpoint Advisors LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.5% in the second quarter, Holdings Channel.com reports. The firm owned 5,777 shares of the company’s stock after selling 471 shares during the period. Centerpoint Advisors LLC’s holdings in Johnson & Johnson were worth $882,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Greenup Street Wealth Management LLC raised its holdings in Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after buying an additional 60 shares in the last quarter. Ellis Investment Partners LLC raised its holdings in Johnson & Johnson by 0.7% during the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after buying an additional 62 shares in the last quarter. Cypress Wealth Services LLC raised its holdings in Johnson & Johnson by 0.9% during the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after buying an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN raised its holdings in Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after buying an additional 64 shares in the last quarter. Finally, Global Strategic Investment Solutions LLC raised its holdings in Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock valued at $294,000 after buying an additional 65 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.0%

JNJ stock opened at $190.31 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company has a market cap of $458.50 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The business’s 50-day simple moving average is $182.54 and its 200 day simple moving average is $166.65. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. HSBC lifted their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Argus set a $210.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, The Goldman Sachs Group lifted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $199.05.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.